Comments
Indoco Remedies received final approval for its ANDA for Febuxostat tablets 40 mg and 80 mg, which is therapeutically equivalent to the drug manufactured by Takeda Pharmaceuticals USA Inc. The market size of Febuxostat tablets in the US is over $500 million. Febuxostat is used for the treatment of gout caused by excessive levels of uric acid in the blood (Hyperuricemia). Febuxostat prevents production of uric acid by blocking the activity of the enzyme (xanthine oxidase) that converts purines to uric acid. Uric acid forms crystals in joints and tissues. Shares of Indoco Remedies down 0.42 per cent at ₹191.60 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.